poisar

Stocks · News reference

B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

Benzinga Newsdesk

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CADL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Candel Therapeutics to Present at the SITC 2026 Annual Meeting

    Candel Therapeutics announced that it will present data from its aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from its phase 1b trial of linoserpaturev in recurrent glioblastoma at the Society for Immunotherapy of Cancer's 41st Annual Meeting in November 2026. The presentations will showcase multi-omics analyses revealing immune activation and improved survival outcomes.

    CADL